Category Archives: Regenerative Medicine

MIAMI (PRWEB) January 30, 2015

Regenestem Network has announced the grand opening of a new stem cells clinic in the prestigious Hospital Clinica de Merida in Yucatan, Mexico. The new clinic will operate under the direction of Gilberto Hernandez Falcon, M.D., a member of the Global Stem Cells Advisory Board and CEO of Regenestem Mexico Sur in Villahermosa Tabasco.

The Yucatan facility is the newest in a growing number of Regenestem clinics providing comprehensive regenerative medicine services worldwide. Plans include equipping the new clinic with the latest technology from the Adilyfe line of stem cell treatment products, made available through Global Stem Cells Group affiliate Adimarket.

Expanding the Regenestem Network throughout Mexico is a great opportunity to bring cutting edge medical advancements to patients, while creating and sustaining new jobs for medical professionals in the Central America region, says Regenestem Founder and CEO Ricardo DeCubas. Were proud to be working with Dr. Hernandez Falcon in making stem cell medicine available to a growing number of patients in the region.

The new Regenestem Yucatan facility will offer the most advanced protocols and techniques available in stem cell medicine.

I am proud to continue to provide stem cell therapies to a wide range of patients here in Mexico and the Central America region, Hernandez Falcon says. Working with the Regenestem Network and Global Stem Cells Group has allowed us to help more and more patients access promising treatments for a range of medical problems.

The Global Stem Cells Group and Regenestem are committed to the highest of standards in service and technology, expert and compassionate care, and a philosophy of exceeding the expectations of their international patients.

For more information, visit the Regenestem Network website, email info(at)regenstem(dot)com, or call 305-224-1858.

About Regenestem:

Regenestem Network, a division of the Global Stem Cells Group, Inc., is an international medical practice association committed to researching and producing comprehensive stem cell treatments for patients worldwide. Having assembled a highly qualified staff of medical specialistsprofessionals trained in the latest cutting-edge techniques in cellular medicineRegenestem continues to be a leader in delivering the latest protocols in the adult stem cell arena. Global Stem Cells Group and Regenestem Network are expanding the companys clinical presence worldwide by partnering with experienced and qualified regenerative medicine physicians to open new clinics licensed and developed under the Regenestem banner. In 2014, Global Stem Cells Group expanded the Regenestem Networks global presence to 20 countries.

View original post here:
Regenestem Network and Gilberto Hernandez Falcon, M.D. Open Stem Cell Clinic in Yucatan

Stanford researchers discover stem cell for bone and cartilage in mice
Researchers at the Stanford Institute for Stem Cell Biology and Regenerative Medicine have discovered the stem cell that makes bone, cartilage and a key comp...

By: institutesofmedicine

View original post here:
Stanford researchers discover stem cell for bone and cartilage in mice - Video

LOS ANGELES (Jan. 27, 2015) - Researchers in the Cedars-Sinai Board of Governors Regenerative Medicine Institute have devised a novel way to generate transplantable corneal stem cells that may eventually benefit patients suffering from life-altering forms of blindness.

Scientists used human corneal cells to generate pluripotent stem cells that have a capacity to become virtually any body cell. Then, putting these cells on natural scaffolds, researcher's facilitated differentiation of these stem cells back to corneal cells.

"Our research shows that cells derived from corneal stem cells are attractive candidates for generating corneal cells in the laboratory," said Alexander Ljubimov, PhD, director of the Eye Program at the Board of Governors Regenerative Medicine Institute and principal investigator on this research study.

This research, published in the journal Stem Cells Translational Medicine, marks an important first step toward creating a bank of corneal stem cells that may potentially benefit patients who suffer from many forms of corneal blindness. The group is now working to optimize the process with National Institutes of Health funding.

Corneal deficiencies may have genetic or inflammatory roots or be caused by injuries, like burns to the skin in occupational accidents. They result in damage or death of stem cells that renew the outermost part of the cornea. If left untreated, they often cause compromised vision or blindness.

Over 150,000 Americans and more than 3 million individuals worldwide are affected by corneal blindness.

###

Study collaborators include Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and professor of biomedical sciences and medicine; Dhruv Sareen, PhD, director of the Induced Pluripotent Stem Cell Core and assistant professor of biomedical sciences; Mehrnoosh Saghizadeh, PhD, assistant professor of biomedical sciences; Yaron Rabinowitz, MD, director of the Division of Ophthalmology Research; and Vincent A. Funari, PhD, director of the Genomics Core and assistant professor of pediatrics.

Citation: Sareen D, Saghizadeh M, Ornelas L, et al. Differentiation of human limbal-derived induced pluripotent stem cells into limbal-like epithelium. Stem Cells Transl Med. 2014; 3(9):1002-12.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

View original post here:
Researchers advance the science behind treating patients with corneal blindness

Nicholasville, Kentucky (PRWEB) January 28, 2015

Cancer Vaccines are few and far between, especially when dealing with canine cancers. In fact, there are only a few viable treatment options available to our beloved pets. MediVet Biologics, a leading provider of in-clinic regenerative medicine services is pleased to announce, K9-ACV a canine cancer vaccine and service applicable to the general practice!

This novel technology has generated excitement and many inquiries since the announcement of its development in early 2015. MediVet Biologics will be hosting a lunch and learn at the Western Vet Conference (WVC) on Tuesday February 17th from Noon to 2PM (PST). The two inventors and industry opinion leaders, Drs. John Yanelli and Don Cohen from the University of Kentucky College of Medicine will be presenting the technology protocols and answering questions.

Also, the progressive conversation continues as Dr. Mike Hutchinson, the Worlds leading Veterinary Regenerative Medicine practitioner, will also be sharing some exciting developments in the field of regenerative medicine. With his 850 stem cell therapy procedures, Dr. Mike has seen it all but he continues to be impressed at the life changing effects stem cell therapy has on his patients.

Please join MediVet Biologics on Tuesday, February 17th from Noon to 2PM (PST) in the Palo Verde room at the Four Seasons for this exciting opportunity to learn about cutting edge technologies!

Space is at a premium and very limited, be sure to pre-register to ensure a seat. All pre-registrants receive a free Cancer Service ($750 value) and are entered to win one of two valuable giveaways! MediVet will be drawing for a free MediVet Stem Cell System or full tuition to the University of Tennessees Certificate program in Canine Rehabilitation (CCRP).

Register online, click here

Or

Contact: Jenny Corbin jenny(at)medivetbiologics(dot)com 859.885.7111 ext. 307

About MediVet Biologics MediVet Biologics headquartered just outside Lexington, KY and Sydney Australia is a subsidiary of Medical Australia (MLA: ASX). MediVet Biologics has global reach including established partners in 26 countries around the world as well as strong market positioning in North America. The company provides novel treatment options based in science to the Veterinary market and provides unique customer specific service plans to ensure implementation and growth of its progressive products and services.

Continued here:
MediVet Biologics announces an exciting speaking engagement at the Western Veterinary Conference (WVC) lead by ...

New York, New York (PRWEB) January 16, 2015

The Leading Physicians of the World and the International Association of HealthCare Professionals are proud to announce that David K. Jin, MD, PhD, is being honored for his exceptional successes as a clinical-scientist in oncology, hematology, and regenerative medicine. Over his many years in practice, Dr. Jin has continued to demonstrate the passion, dedication, and enthusiasm for patient care necessary to be considered a Top Clinician, Scientist, and Researcher in his field.

Dr. Jin is currently the Chief Medical Officer of BioTime Inc. as well as its subsidiary OncoCyte Corporation and BioTime Asia Limited. His passion has been to develop novel products for the treatment and diagnosis based on stem cell-derived technology in order to improve both the quality and length of life of patients. Dr. Jin is a clinician and a scientist dedicated to the fields of oncology, hematology, regenerative medicine, and cancer immunotherapy. His work includes his role in various regulatory agencies internationally as medical reviewers as well as Chief Consultant and Advisor for various biotechnology and pharmaceutical companies regarding hematology, oncology, and stem cell-based technology development. Dr. Jin is also a published author and co-author with more than 80 peer reviewed articles, scientific abstracts, reviews, and book chapters featured in publications such as Nature, Nature Medicine, Cell, PNAH, and JCI. He was formerly affiliated with New York-Presbyterian Hospital-Ansary Stem Cell Institute.

Dr. Jin studied medicine at SUNY Downstate Medical Centers College of Medicine in Brooklyn, New York. Established 140 years ago, the school truly revolutionized medical education in the United States as the first medical school founded within a hospital, making bedside training an integral part of students' education. Upon his graduation in 2000, Dr. Jin pursued further clinical training, including his fellowship in hematology and oncology at NewYork-Presbyterian Hospital, where he subsequently received faculty tenure. The NewYork-Presbyterian Hospital is the teaching hospital for both Cornell and Columbia Universities in the areas of internal medicine, hematology, and clinical oncology. Moreover, Dr. Jin has been senior translational scientist at the Howard Hughes Medical Institute and the Ansary Center for Stem Cell Therapeutics at Cornell. His discovery of the chemokine-driven hemangiocytes (bone marrow-derived CXCR4- and VEGFR1-expressing hematopoietic stem cells) in 2006 has had significant impact on the understanding of stem cell mobilization, angiogenesis, and stem cell niche theory. In 2012, Dr. Jin was honored as Top Chief Medical Officer and has been principle investigator in more than 15 pre-clinical and clinical trials as well as translation researcher in stem biology, cancer, and vascular medicine.

To find out more about Dr. Jin, please visit http://www.biotimeinc.com or http://www.oncocyte.com. Also be sure to look out for his upcoming publication in The Leading Physicians of the World.

To find a Doctor by Specialty and Zip Code, please visit http://www.findatopdoc.com and book your appointment online instantly.

Link:
Eminent Clinician and Scientist in Oncology, Hematology, and Regenerative Medicine, David K. Jin, MD, PhD, Inducted ...

Poway, California (PRWEB) January 16, 2015

January 16th, 2015 Leading Regenerative Veterinary Medicine company, Vet-Stem, Inc., CEO announced the hiring of President and Chief Commercial Officer, Alexis Nahama, DVM.

After ten years of market presence, serving early adopter and progressive veterinarians, we are ready to take our company to the next level. We are heavy on science, and have engaged in the development of our next generation of therapeutic solutions, including working with the FDA towards obtaining approval for the first veterinary cellular therapy product to be used in helping dogs affected by osteoarthritis. In addition to its aim of reducing the pain of osteoarthritis, this therapy has the potential to impact the progression of the disease, and to promote tissue regeneration. Given the complexities of such developments, I have decided to focus most of my time to our research programs. I needed a great partner to take on the current operations and focus our commercial approach, said Dr Bob Harman (CEO).

Dr. Harman and the board of directors announced the appointment of Dr. Alexis Nahama as the new Vet-Stem, Inc.s President and Chief Commercial Officer.

Dr. Nahama, former head of marketing for VCA Inc. (Nasdaq: Woof), brings two decades of global veterinary industry experience with him, ranging from clinical development to managing some of the most influential brands in animal health.

Our current technology has helped over 10,000 dogs, horses and cats through processing of their own fat tissue to extract stem cells that are then injected in painful joints, tendons or ligaments, but many owners are still unaware we have a possible solution for their animals need. Although not inexpensive, (great breakthrough technologies seldom are) this therapeutic approach is already available through many veterinarians today! said Dr Nahama.

Vet-Stem Inc., despite its relatively small size has the potential to dramatically change the way veterinarians address difficult diseases in the not so distant future. In a world of giant corporations, this company will be truly disruptive and benefit countless patients worldwide. It is with great pride and excitement that I take on these responsibilities and join this amazingly smart and dedicated group of people,added Dr. Nahama.

Alexis passion for helping pet owners and veterinarians, coupled with his extensive knowledge of the veterinary industry and his marketing expertise, is exactly what we need to succeed, stated Dr. Harman. I am happy to welcome him to be part of our leadership team.

About Vet-Stem, Inc. Vet-Stem, Inc. was formed in 2002 to bring regenerative medicine to the veterinary profession. This privately held biotechnology enterprise, based near San Diego (California), currently offers veterinarians access to stem-cell therapy (extracted from the patients own fat tissue), among other regenerative treatment modalities. With over 10,000 patients treated by veterinarians for joint, tendons and ligament issues, Vet-Stem has made regenerative medicine applications a therapeutic reality beyond the realm of research. Development programs focused on products and services that utilize the natural tissue healing properties inherent in all living creatures, have the potential to dramatically improve the quality of life for our animals Vet-Stems progress in bringing practical and affordable medical solutions to market might change animal lives by improving the quality of recovery in acute conditions, but also by unlocking ways to slow, stop and ultimately revert the course of chronic diseases.. Vet-Stem currently holds the exclusive licenses to over 55 patents including worldwide veterinary rights for use of adipose derived stem cells, with over 75 patents pending.

12860 Danielson Court, Suite B Poway, CA 92064 858-748-2004

Read the rest here:
Vet-Stem, Inc. CEO announces hiring of President and Chief Commercial Officer (Dr. Alexis Nahama).

Contact Information

Available for logged-in reporters only

Newswise A new study by researchers at Childrens Hospital Los Angeles has shown that tissue-engineered small intestine grown from human cells replicates key aspects of a functioning human intestine. The tissue-engineered small intestine they developed contains important elements of the mucosal lining and support structures, including the ability to absorb sugars, and even tiny or ultra-structural components like cellular connections.

Published online January 8 by the American Journal of Physiology: GI & Liver, the work brings surgeons one step closer to helping human patients using this regenerative medicine technique.

Tissue-engineered small intestine (TESI) grows from stem cells contained in the intestine and offers a promising treatment for short bowel syndrome (SBS), a major cause of intestinal failure, particularly in premature babies and newborns with congenital intestinal anomalies. TESI may one day offer a therapeutic alternative to the current standard treatment, which is intestinal transplantation, and could potentially solve its largest challenges donor shortage and the need for lifelong immunosuppression.

Tracy C. Grikscheit, MD, a principal investigator in The Saban Research Institute of CHLA and its Developmental Biology and Regenerative Medicine program, is also a pediatric surgeon at Childrens Hospital Los Angeles and an assistant professor of surgery at the Keck School of Medicine of the University of Southern California.

Grikscheit aims to help her most vulnerable young patients, including babies who are born prematurely and develop a devastating disease called necrotizing enterocolitis (NEC), where life-threatening intestinal damage requires removal of large portions of the small intestine. Without enough intestinal length, the babies are dependent on intravenous feeding, which is costly and may cause liver damage. NEC and other contributors to intestinal failure occur in 24.5 out of 100,000 live births, and the incidence of SBS is increasing. Nearly a third of patients die within five years.

CHLA scientists had previously shown that TESI could be generated from human small intestine donor tissue implanted into immunocompromised mice. However, in those initial studies published in July 2011 in the biomedical journal Tissue Engineering, Part A only basic components of the intestine were identified. For clinical relevance, it remained necessary to more fully investigate intact components of function such as the ability to form a healthy barrier while still absorbing nutrition or specific mechanisms of electrolyte exchange.

The new study determined that mouse TESI is highly similar to the TESI derived from human cells, and that both contain important building blocks such as the stem and progenitor cells that will continue to regenerate the intestine as a living tissue replacement. And these cells are found within the engineered tissue in specific locations and in close proximity to other specialized cells that are known to be necessary in healthy human intestine for a fully functioning organ.

We have shown that we can grow tissue-engineered small intestine that is more complex than other stem cell or progenitor cell models that are currently used to study intestinal regeneration and disease, and proven it to be fully functional as it develops from human cells, said Grikscheit. Demonstrating the functional capacity of this tissue-engineered intestine is a necessary milestone on our path toward one day helping patients with intestinal failure.

Here is the original post:
Researchers Grow Functional Tissue-Engineered Intestine from Human Cells

Nicholasville, Kentucky (PRWEB) January 06, 2015

MediVet America, the catalyst of the MediVet brand as the worlds leader in Veterinary regenerative medicine will announce on Jan 6, 2015 a change in name to MediVet Biologics. The new brand includes a new logo, company mission and customer materials. A new website will also launch today, improving users online experience. The rebranding reflects the many recent changes the company has undergone globally uniting the Veterinary holdings of Medical Australia (MLA:ASX) which include MediVet America, TutaVet & MediVet Pty Ltd. The rebranding will also serve to better define the products and services offered by MediVet for the large and small animal market as well as its vision for the future.

MediVet serves an international progressive network of thousands of veterinarians with products such as Platelet Rich Plasma, Adipose Derived Stem Cell Treatments, and Autologous Conditioned Serum (IRAP ACS). The company has several Research and Development projects in the pipeline including other breakthrough biologic therapies coming to market in 2015.

In an effort to continue the advancement of the animal regenerative medicine space and provide the most, efficacious, and widely used provider of these therapies, MediVet Biologics continues to invest in the research and validation of the science. As of January 6th, 2015 the company has several ongoing R&D studies/projects at, The University of Kentucky, College of Medicine, University of Georgia College of Veterinary Medicine, & Kansas State University.

Our in-clinic adipose derived stem cell treatments have been very well received by the North American Veterinary market and have allowed us to assist animals as well as add brick and mortar value to Veterinarian practices in a shifting and dynamic market. We look forward to expanding our brand domestically in the US as well as globally, Jeremy Delk, C.E.O. MediVet Biologics.

About MediVet Biologics MediVet Biologics headquartered just outside Lexington, Kentucky and Sydney, Australia. Medivet Biologics is a subsidiary of Medical Australia (MLA: ASX). MediVet Biologics has global reach including established partners in 26 countries around the world as well as strong market positioning in North America. The company provides novel treatment options based in science to the Veterinary market as well as provide unique customer specific service plans to ensure implementation and growth of its progressive products and services.

Medivet Biologics' mission is to set standards of excellence for providing biologic solutions to the veterinary market. Our companys success, which is characterized by responsiveness and clinical excellence, has been founded on our dedication and quality innovative technologies. Veterinarians and pet owners trust MediVet Biologics to provide the quality care they expect and deserve. By providing services as though each pet were a member of our family, MediVet Biologics strives to be the preferred provider of Veterinary Regenerative Medicine products, equipment and services.

Read the original here:
MediVet America to Re-brand as MediVet Biologics

VAIL Regenerative medicine, including stem cells, seems miraculous, so of course the demand far outstrips the pace at which research can create a supply.

The medical and scientific community are doing everything they can, but the demand for them always outpaces their availability. Research take a long time, said Dr. David Karli with the Steadman Clinic.

The Vail Symposium is gathering three experts in the field to discuss whats available, what the limitations are, and whats in the pipeline. The program, The Patient Consumer: Navigating the Waters of Regenerative Medicine, takes place Thursday at Vail Mountain School. Along with Karli, Dr. Chris Centeno and Dr. Maynard Howe also are on the panel.

OUTSTANDING PANEL

The Vail Symposium had its first stem cell program last year, outlining the progress of stem cell science, said the Symposiums Dale Mosier. It was so fascinationg they decided to do one every year, Mosier said.

This years presenters have been doing stem cell/regenerative medicine for many years and they have the successful history in different applications many patients to make for an outstanding panel, Mosier said.

Thursdays panel will be moderated by Rohn Robbins.

What is it?

Regenerative medicine is anything that would facilitate regenerative healing in the body, Karli said.

It works best for body parts that dont heal well on their own because they lack a good blood supply. If you pull a muscle, it heals because blood carries healing properties to the injury, Karli explained.

Read the rest here:
Regenerative medicine program set for Thursday in Vail

Mayo Clinic #39;s Dr. Shane Shapiro Discussing Latest in Stem Cell Research at #WSCS14
Dr. Shane Shapiro, orthopedic physician, discussing highlights of stem cell research and regenerative medicine from the Mayo Clinic in Florida campus, during...

By: Mayo Clinic

Link:
Mayo Clinic's Dr. Shane Shapiro Discussing Latest in Stem Cell Research at #WSCS14 - Video